SRA-737, an oral small-molecule CHK1 inhibitor, is undergoing clinical trials for various solid tumors, including small-cell lung cancer (SCLC) (NCT0279964, NCT02797977) [248]. Here, CHEK1 is linked to small cell lung carcinoma.